FHTX Q1 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-4.9% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$28M-558.3% margin

Net Income

-$25M-495.4% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

-12.5%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$255M

Total Liabilities

$352M

Stockholders' Equity

-$97M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$5M	-4.9%
Gross Profit	$5M	$5M	-4.9%
Operating Income	-$28M	-$33M	+15.4%
Net Income	-$25M	-$30M	+17.9%